The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong, SAR China.
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Endocrinol (Lausanne). 2021 Oct 21;12:704496. doi: 10.3389/fendo.2021.704496. eCollection 2021.
Insidious-onset acromegaly may easily be overlooked by non-specialists of acromegaly and cause diagnostic delay. This study aims to examine the association between diagnostic delay and advice from doctors before any confirmed diagnosis and subsequent comorbidities, and elicit patient-perceived reasons for misdiagnoses.
An online nationwide cross-sectional study was conducted through China Acromegaly Patient Association. Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) levels at diagnosis and cancerous, endocrine-metabolic, musculoskeletal, cardiovascular, respiratory, and psychiatric comorbidities were reported by patients. The association between diagnostic delay and pre-diagnostic advice from doctors as well as subsequent comorbidities after diagnosis were examined.
In total, 447 valid responses were collected. Overall, 58.8% patients experienced misdiagnoses, and 22.6% had diagnostic delay. Before arriving at any diagnosis, patients without treatment (adjusted odds ratio [AOR]: 3.66, 95% confidence interval [CI]: 1.30-10.33) or receiving treatment to symptoms only (AOR: 7.05, 95%CI: 4.09-12.17) had greater chance of being misdiagnosed, and hence had diagnostic delay. Patients believed insufficient specialists, limited awareness of acromegaly of non-specialists and poor doctor-patient communications were major reasons of misdiagnosis. Diagnostic delay were associated with higher GH level at diagnosis and endocrine-metabolic, musculoskeletal and cardiovascular comorbidities (all P<0.05).
Suboptimal pre-diagnostic advice for patients, reflecting limited awareness of acromegaly among non-specialists, may delay the diagnosis and increase comorbidities. Feedbacks on the patients' final diagnosis from specialists to non-specialists should be considered, and doctor-patient communication and clinical decision-making process should be improved. Comorbidities should be screened and monitored particularly for patients with diagnostic delay.
隐匿性起病的肢端肥大症很容易被肢端肥大症的非专科医生忽视,导致诊断延迟。本研究旨在探讨诊断延迟与确诊前医生的建议以及随后的合并症之间的关系,并找出导致误诊的患者认为的原因。
通过中国肢端肥大症患者协会进行了一项全国范围内的在线横断面研究。患者报告了诊断时的生长激素(GH)和胰岛素样生长因子 1(IGF-1)水平以及癌症、内分泌代谢、肌肉骨骼、心血管、呼吸和精神合并症。研究了诊断延迟与确诊前医生的建议以及诊断后随后发生的合并症之间的关系。
共收集了 447 份有效回复。总体而言,58.8%的患者经历了误诊,22.6%的患者存在诊断延迟。在做出任何诊断之前,未接受治疗(调整后的优势比 [AOR]:3.66,95%置信区间 [CI]:1.30-10.33)或仅接受症状治疗(AOR:7.05,95%CI:4.09-12.17)的患者更有可能被误诊,因此存在诊断延迟。患者认为缺乏专科医生、非专科医生对肢端肥大症的认识有限以及医患沟通不畅是误诊的主要原因。诊断延迟与诊断时较高的 GH 水平以及内分泌代谢、肌肉骨骼和心血管合并症相关(均 P<0.05)。
患者的预诊断建议不理想,反映了非专科医生对肢端肥大症的认识有限,这可能会延迟诊断并增加合并症。应考虑将专科医生对患者最终诊断的反馈提供给非专科医生,并应改进医患沟通和临床决策过程。应特别对诊断延迟的患者进行合并症筛查和监测。